Weight Reduction by Sibutramine in Obese Subjects in Primary Care Medicine: The S. A. T. Study

 

 Buy Article Permissions and Reprints

Abstract

Background: Sibutramine is a selective serotonin and noradrenaline reuptake inhibitor that is known to reduce body weight. The efficacy of this drug in primary care medicine is currently unknown.

Objective: To study, in a primary healthcare setting, the effect of a standardized non-pharmacological treatment program and 15 mg sibutramine or placebo on long-term weight reduction in obese subjects with a body mass index ≥ 30 and < 40 kg/m².

Design: A multicentre, double-blind, placebo-controlled, randomized, parallel group comparison over 54 weeks of continuous therapy.

Setting: 33 general practitioners in Germany.

Subjects: 389 obese patients were recruited of whom 362 were randomized.

Measurements: Primary measure was weight reduction at week 54; others included reduction in BMI, waist circumference, waist-hip ratio, blood pressure and blood lipids.

Results: 348 obese subjects were analyzed using an intention-to-treat analysis. Mean weight loss in the sibutramine (S) group was 8.1 ± 8.2 kg vs. 5.1 ± 6.5 kg in the placebo (P) group (p < 0.001; Intent-to-treat analysis). More subjects lost more than 5 % and 10 % of initial weight with sibutramine than with placebo (5 %, S: 62.6 %, P: 41.4 %, p < 0.001; 10 %, S: 40.8, P: 19.0 %, p < 0.001). Weight loss was accompanied by an improvement in the lipid profile, in particular, an increase in HDL-cholesterol and a decrease in fasting triglycerides. In both groups, systolic and diastolic blood pressure decreased in those with moderate hypertension and remained unchanged in those with normal blood pressure at baseline. There was a modest increase in heart rate in S (1.9 beats/min) vs. P (- 0.9 beats/min) (p < 0.05).

Conclusions: Under primary care conditions, sibutramine 15 mg daily proved to be a safe and effective drug for additional weight loss in obese subjects undergoing a comprehensive weight reduction program.

References

• 1 Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.  Am J Med. 1999;  106 179-184
  CrossrefPubMedGoogle Scholar
• 2 Birkenfeld A L, Schroeder C, Boschmann M, Tank J, Franke G, Luft F C, Biaggioni J, Sharma A M, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation.  Circulation. 2002;  106 2459-246
  CrossrefPubMedGoogle Scholar
• 3 Bray G A, Blackburn G L, Ferguson J M, Greenway F L, Jain A K, Mendel C M, Mendels J, Ryan D H, Schwartz S L, Scheinbaum M L, Seaton T B. Sibutramine produces dose-related weight loss.  Obes Res. 1999;  7 189-198
  PubMedGoogle Scholar
• 4 Expert Panel on the Identification .Clinical Guidelines On the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. The Evidence Report. Bethesda; National Institute of Health, National Heart, Lung and Blood Institute 1998
  Google Scholar
• 5 Fleiss J L. The Design and Analysis of Clinical Experiments. Hoboken, New Jersey; John Wiley & Sons 1986
  Google Scholar
• 6 Hanotin C, Thomas F, Jones S P, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.  Int J Obes Relat Metab Disord. 1998;  22 32-38
  CrossrefPubMedGoogle Scholar
• 7 Hansen D L, Toubro S, Stock M J, Macdonald I A, Astrup A. Thermogenic effects of sibutramine in humans.  Am J Clin Nutr. 1998;  68 1180-1186
  PubMedGoogle Scholar
• 8 James W PT, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris W H, van Gaal L F. for the STORM Study Group . Effect of sibutramine on weight maintenance after weight loss: a randomized trial.  Lancet. 2000;  356 2119-2125
  CrossrefPubMedGoogle Scholar
• 9 Lean M EJ. Sibutramine - a review of clinical efficacy.  Int J Obes Rel Metab Disord. 1997;  21 (Suppl 1) S30-S36
  PubMedGoogle Scholar
• 10 National Task Force on the Prevention and Treatment of Obesity . Long-term pharmacotherapy in the management of obesity.  JAMA. 1996;  276 1907-1915
  CrossrefPubMedGoogle Scholar
• 11 Perri M G, Nezu A M. Preventing relapse following treatment for obesity. Stunkard AJ, Wadden TA Obesity: Theory and Therapy. New York; Raven Press 1993: 288-299
  Google Scholar
• 12 Pi-Sunyer F X. Medical hazards of obesity.  Ann Intern Med. 1993;  110 655-660
  PubMedGoogle Scholar
• 13 Report of a WHO consultation on obesity. Obesity - Preventing and Managing the Global Epidemic. WHO Geneva; WHO Technical Report Series 894 2000
  Google Scholar
• 14 Rolls B J, Shide D J, Thorwart M L, Ulbrecht J S. Sibutramine reduces food intake in non-dieting women with obesity.  Obes Res. 1998;  6 1-11
  PubMedGoogle Scholar
• 15 Royal College of Physicians .Overweight and Obese Patients. Principles of Management with Particular Reference to the Use of Drugs. London; 1997
  Google Scholar
• 16 Stock M J. Sibutramine: a review of the pharmacology of a novel anti-obesity drug.  Int J Obes Relat Metab Disord. 1997;  2 (Suppl 2) S25-S29
  PubMedGoogle Scholar
• 17 Walsh K M, Leen E, Lean M E. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females.  Int J Obes Rel Metab Disord. 1999;  23 1009-1015
  PubMedGoogle Scholar
• 18 Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial.  JAMA. 2001;  286 1331-1339
  CrossrefPubMedGoogle Scholar

M. D. Hans Hauner

Else-Kröner-Fresenius-Zentrum für Ernährungsmedizin der TU München
Klinikum Rechts der Isar

Ismaninger Straße 22

81675 München

Germany

Phone: + 498941406770

Fax: + 49 89 41 40 67 72

Email: hauner@wzw.tum.de